A Phase 1 interventional study of 89Zr-MMOT0530A in Ovarian Neoplasms, Ovarian Diseases and Adnexal Diseases, sponsored by University Medical Center Groningen. Completed at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-03.
Sponsored by University Medical Center Groningen · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies in Ovarian Neoplasms with a site in Netherlands — 24 open to participants now, 37 under way, 13 of them phase 3. Ovarian Neoplasms · Netherlands.
Among the 130 studies in Ovarian Neoplasms with a site in Netherlands, this one is the 109th largest by enrollment of the 116 interventional ones that give a count, is one of 7 that started in 2013, is one of 23 in phase 1, and was the 48th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →24 of the 130 studies in Ovarian Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Sites in Netherlands, United States, Argentina and 19 more countries
Ages 18+ · Women only
Eli Lilly and Company · Sites in Netherlands, United States, China and 2 more countries
Ages 18+
Eli Lilly and Company · Sites in Netherlands, United States, Australia and 24 more countries
Ages 18+
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18–100 · Women only
Amsterdam UMC, location VUmc · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 44 · Phase 3 37 · Phase 4 2
First in 1995; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 210 across the 116 interventional studies, 500 across the 13 observational. Of the 83 that completed or were terminated, 27 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 130 have an industry lead sponsor. The 10 most frequent:
University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 175 are open to participants now.
University Medical Center Groningen has 8 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
8 of the studies in Ovarian Neoplasms with a site in Netherlands that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06476184Phase 3ARCAGY/ GINECO GROUPUtility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery | 2027-06 |
| NCT07214779Phase 3Incyte CorporationStudy to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | 2027-10-12 |
| NCT04954599Maastricht University Medical CenterPhase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | 2027-02 |
| NCT07460180The Netherlands Cancer InstituteThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer | 2027-05-01 |
| NCT03564340Regeneron PharmaceuticalsStudy of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | 2027-05-10 |
Add all 8 to your calendar (.ics) → With an account.
Among the 130 studies in Ovarian Neoplasms with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this multicenter imaging sub study is to evaluate the biodistribution and organ pharmacokinetics of 89Zr-MMOT0530A in patients with unresectable pancreatic or platinum-resistant ovarian cancer. MMOT0530A is a monoclonal antibody that targets an antigen overexpressed in pancreatic and ovarian cancer. Subsequent to imaging with 89Zr-MMOT0530A, patients will be treated with DMOT4039A in the DMO4993g protocol (clinicaltrials.gov identifier NCT01469793) after this study. DMOT4039A is an antibody-drug conjugate composed of the monoclonal antibody MMOT0530A and the mitotic agent monomethyl auristatin (MMAE). By imaging patients with the monoclonal antibody MMOT0530A before treatment, the correlation between tumor uptake of 89Zr-MMOT0530A and response to DMOT4039A therapy will be assessed.
A challenge in current drug development using molecular targeted therapies is the high level of heterogeneity that is present in specific tumor types. The ability to safely and accurately predict the presence or absence of the target is essential for the therapeutic effect of the newly developed drugs. DMOT0439A is one of those novel designed molecular targeted drugs; an antibody-drug conjugate composed of the monoclonal antibody MMOT0530A and the mitotic agent monomethyl auristatin (MMAE). In the DMO4993g protocol (clinicaltrials.gov identifier NCT01469793), the safety and efficacy of DMOT4039A is assessed in patients with unresectable pancreatic or platinum-resistant ovarian cancer. By performing a 89Zr-MMOT0530A PET scan prior to treatment with DMOT4039A, the uptake of the tracer in the primary and metastatic tumor lesions can be evaluated. This is likely to provide important information about target expression, whole body drug distribution and the correlation between tumor uptake and response to therapy. Ultimately the use of a 89Zr- MMOT0530A PET as a complimentary tool for patient selection and risk stratification can be evaluated. In part A of this study, the optimal tracer dose of 89Zr- MMOT0530A and schedule for PET imaging will be determined. In part B patients will have PET imaging before treatment in the DMO4993g study on the dose and time points as assessed in part A.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
Drug: 89Zr-MMOT0530A
Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
Also known as: MMOT
The in vivo biodistribution measured in SUV values and organ pharmacokinetics (PK) of 89Zr-MMOT0530A
* The accumulation, distribution and localization of 89Zr-MMOT0530A in tumor tissue, organs and blood circulation, as assessed by PET. * The quantitative uptake of 89Zr-MMOT0530A expressed in SUV (Standardized Uptake value).
Time frame: Approximately 1 year
The 89Zr-MMOT0530A tumor uptake measured in SUV related to the response to DMOT4039A therapy according to RECISt 1.1 criteria
The correlation between the 89Zr-MMOT0530A tumor uptake and response to therapy by performing an 89Zr-MMOT0530A PET scan before DMOT4039A therapy, related to CT/MRI response according to RECIST 1.1 criteria.
Time frame: Approximately 1 year
Number of patients with adverse events after 89Zr-MMOT0530A injection as a measure of safety and tolerability
Safety will be assessed by evaluation of incidence of adverse events.
Time frame: Approximately 1 year
The record gives a start of Mar 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Center Groningen →